1. Scrip

AstraZeneca Sees SOURCE Tezepelumab Failure In Asthma

Comes After Delay For Roxadustat In The US

 
• By Alexandra Shimmings

The SOURCE failure is a reversal for the novel Amgen-partnered TSLP inhibitor after NAVIGATOR success last month, and comes just days after the US FDA requested more analyses of the pivotal data for the kidney disease anemia therapy roxadustat.

Bumps In the road • Source: Shutterstock

AstraZeneca PLC has had a disappointing few days with two novel products, with the topline failure of the Phase III SOURCE study of its asthma candidate tezepelumab coming on top of a US approval delay for the anemia in kidney disease therapy roxadustat, announced on 18 December. The UK company had better news, however, with the expanded US approval for Tagrisso (osimertinib) for early-stage EGFR mutant non-small cell lung cancer on the ADUARA study on 21 December.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.